Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOCRYST PHARMACEUTICALS INCBCRX · Entity 315 | Director | June 20, 2018 | June 22, 2018 |
| CareDx, Inc.CDNA · Entity 4344 | Director | June 12, 2026 | June 16, 2026 |
| FIVE PRIME THERAPEUTICS, INC.FPRX · Entity 16595 | Director | May 10, 2017 | May 12, 2017 |
| Intellia Therapeutics, Inc.NTLA · Entity 4585 | Director | June 09, 2026 | June 10, 2026 |
| Kyverna Therapeutics, Inc.KYTX · Entity 5452 | Director | May 27, 2026 | May 29, 2026 |
| Progyny, Inc.PGNY · Entity 4521 | Director | May 23, 2024 | May 29, 2024 |
| Roka BioScience, Inc.ROKA · Entity 172682 | Director | June 28, 2017 | June 30, 2017 |
| TANDEM DIABETES CARE INCTNDM · Entity 4682 | Director | November 15, 2018 | November 19, 2018 |
| UroGen Pharma Ltd.URGN · Entity 4466 | Director | August 06, 2024 | August 08, 2024 |
| VERACYTE, INC.VCYT · Entity 2018 | Director | October 19, 2020 | October 20, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOCRYST PHARMACEUTICALS INC
Report date June 20, 2018 · Filed June 22, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Automatic Stock Option GrantSEC Table II · derivative / convertible security · Conversion / exercise price $6.09 · Expires 2028-06-20 | Direct | 30,000 |
Reported balance
After 2018-06-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-06-20 · Grant · Acquired 30,000 · Balance 30,000 F1: Automatic non-employee director grant pursuant to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan. F2: Vests 1/12th per month over twelve months beginning July 20, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: Automatic non-employee director grant pursuant to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan.
F2: Vests 1/12th per month over twelve months beginning July 20, 2018.
CareDx, Inc.
Report date June 12, 2026 · Filed June 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 165,060 |
Reported balance
After 2026-06-12 transaction · row 1
1 source rowRow 1 · 2026-06-12 · Grant · Acquired 9,795 · Balance 165,060 F1: The reported securities are represented by restricted stock units ("RSUs"), of which the RSUs vests 100% on the earlier of the one year anniversary of grant or the day immediately before the first Annual Meeting that occurs after the grant date., subject to the Reporting Person's continuous service on each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities are represented by restricted stock units ("RSUs"), of which the RSUs vests 100% on the earlier of the one year anniversary of grant or the day immediately before the first Annual Meeting that occurs after the grant date., subject to the Reporting Person's continuous service on each applicable vesting date.
FIVE PRIME THERAPEUTICS, INC.
Report date May 10, 2017 · Filed May 12, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.80 · Expires 2027-05-09 | Direct | 10,000 |
Reported balance
After 2017-05-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-05-10 · Grant · Acquired 10,000 · Balance 10,000 F1: This option will vest in its entirety on the earlier to occur of (i) May 10, 2018 or (ii) the day before the 2018 annual meeting of stockholders of Five Prime Therapeutics, Inc. (the "Company"), subject to the reporting person's continued service to the Company through such vest date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option will vest in its entirety on the earlier to occur of (i) May 10, 2018 or (ii) the day before the 2018 annual meeting of stockholders of Five Prime Therapeutics, Inc. (the "Company"), subject to the reporting person's continued service to the Company through such vest date.
Intellia Therapeutics, Inc.
Report date June 09, 2026 · Filed June 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 216,653 |
Reported balance
After 2026-06-09 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-09 · Grant · Acquired 9,200 · Balance 216,653 F1: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.89 · Expires 2036-06-08 | Direct | 13,300 |
Reported balance
After 2026-06-09 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-09 · Grant · Acquired 13,300 · Balance 13,300 F2: This option was granted on June 9, 2026 with respect to 13,300 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.
F2: This option was granted on June 9, 2026 with respect to 13,300 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant.
Kyverna Therapeutics, Inc.
Report date May 27, 2026 · Filed May 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 21,727 |
Reported balance
After 2026-05-27 transaction · row 1
1 source rowRow 1 · 2026-05-27 · Grant · Acquired 5,093 · Balance 21,727 F1: Represents a restricted stock unit award of common stock, which will vest in full on the earlier of (i) May 27, 2027, and (ii) immediately prior to the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.59 · Expires 2036-05-27 | Direct | 20,582 |
Reported balance
After 2026-05-27 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-05-27 · Grant · Acquired 20,582 · Balance 20,582 F2: All of the shares subject to the option shall be fully vested and exercisable on the earlier of (i) May 27, 2027, and (ii) immediately prior to the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 4,523,924 |
Reported balance
Holding disclosure · report date 2026-05-27 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 4,523,924 F3: Shares held directly by Vida Ventures, LLC ("Vida"). Vida Ventures Advisors, LLC is the investment advisor to Vida. Dr. Arie Belldegrun, Leonard Potter and the Reporting Person are the managing members of Vida Ventures Advisors, LLC, and may be deemed to share voting and dispositive power over the shares held by Vida, but each disclaims beneficial ownership of the shares held by Vida except to the extent of such person's pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a restricted stock unit award of common stock, which will vest in full on the earlier of (i) May 27, 2027, and (ii) immediately prior to the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.
F2: All of the shares subject to the option shall be fully vested and exercisable on the earlier of (i) May 27, 2027, and (ii) immediately prior to the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.
F3: Shares held directly by Vida Ventures, LLC ("Vida"). Vida Ventures Advisors, LLC is the investment advisor to Vida. Dr. Arie Belldegrun, Leonard Potter and the Reporting Person are the managing members of Vida Ventures Advisors, LLC, and may be deemed to share voting and dispositive power over the shares held by Vida, but each disclaims beneficial ownership of the shares held by Vida except to the extent of such person's pecuniary interest therein, if any.
Progyny, Inc.
Report date May 23, 2024 · Filed May 29, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 22,693 |
Reported balance
After 2024-05-23 transaction · row 1
1 source rowRow 1 · 2024-05-23 · Grant · Acquired 6,176 · Balance 22,693 F1: Represents the number of shares of Issuer common stock underlying restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs will vest on May 23, 2025, subject to the Reporting Person's continued service on such date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.15 · Expires 2034-05-22 | Direct | 25,070 |
Reported balance
After 2024-05-23 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-05-23 · Grant · Acquired 25,070 · Balance 25,070 F2: The shares subject to the option will vest on May 23, 2025, subject to the Reporting Person's continued service on such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares of Issuer common stock underlying restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs will vest on May 23, 2025, subject to the Reporting Person's continued service on such date.
F2: The shares subject to the option will vest on May 23, 2025, subject to the Reporting Person's continued service on such date.
Roka BioScience, Inc.
Report date June 28, 2017 · Filed June 30, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.55 · Expires 2027-06-27 | Direct | 3,000 |
Reported balance
After 2017-06-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-06-28 · Grant · Acquired 3,000 · Balance 3,000 |
TANDEM DIABETES CARE INC
Report date November 15, 2018 · Filed November 19, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $33.12 | Direct | 25,000 |
Reported balance
After 2018-11-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-11-15 · Grant · Acquired 25,000 · Balance 25,000 F1: Granted pursuant to the Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan. F2: All shares subject to the option will vest in equal monthly installments over 12 months. F3: The expiration date for these options is 10 years from the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Granted pursuant to the Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan.
F2: All shares subject to the option will vest in equal monthly installments over 12 months.
F3: The expiration date for these options is 10 years from the date of grant.
UroGen Pharma Ltd.
Report date August 06, 2024 · Filed August 08, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right ot buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.16 · Expires 2034-08-06 | Direct | 10,000 |
Reported balance
After 2024-08-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-08-06 · Grant · Acquired 10,000 · Balance 10,000 F1: The shares underlying the stock option will vest in equal quarterly installments over a period of one year, subject to the director's Continuous Service (as defined in the 2017 Equity Incentive Plan) through such vesting dates. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying the stock option will vest in equal quarterly installments over a period of one year, subject to the director's Continuous Service (as defined in the 2017 Equity Incentive Plan) through such vesting dates.
VERACYTE, INC.
Report date October 19, 2020 · Filed October 20, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 10,000 |
Reported balance
After 2020-10-19 transaction · row 1
1 source rowRow 1 · 2020-10-19 · Exercise / conversion · Acquired 10,000 · Balance 10,000 |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.60 · Expires 2028-06-07 | Direct | 0 |
Reported balance
After 2020-10-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-10-19 · Exercise / conversion · Disposed 10,000 · Balance 0 F1: The option is fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: The option is fully vested.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
GENOMIC HEALTH INC
Report date November 08, 2019 · Filed November 14, 2019
Section 16 reporting ended · disclosed 2019-11-14. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2019-11-08 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2019-11-08 · Disposition to issuer · Disposed 68,165 · Balance 955 F1: Disposed of in connection with the acquisition of Issuer (the "Merger") by Exact Sciences Corporation ("Exact Sciences") pursuant to the Agreement and Plan of Merger, dated July 28, 2019 (the "Merger Agreement"), among Exact Sciences, Spring Acquisition Corp., and Issuer, whereby such shares of Issuer common stock were cancelled and converted into the right to receive a cash payment of $1,874,586 and 30,703 shares of Exact Sciences common stock, having a market value of $79.95 per share, based on the closing price of Exact Sciences common stock on November 7, 2019. Row 2 · 2019-11-08 · Disposition to issuer · Disposed 955 · Balance 0 F2: Disposed of in connection with the Merger, whereby such Issuer restricted stock unit award, whether or not vested, was cancelled in exchange for a cash payment of $26,277 and 430 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019. |
| Common StockSEC Table I · non-derivative | IndirectBy the Jane K Cohen Trust | 0 |
Reported balance
After 2019-11-08 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2019-11-08 · Disposition to issuer · Disposed 6,068 · Balance 0 F3: Disposed of in connection with the Merger pursuant to the Merger Agreement, whereby such shares of Issuer common stock were cancelled and converted into the right to receive a cash payment of $166,888 and 2,733 shares of Exact Sciences common stock, having a market value of $79.95 per share, based on the closing price of Exact Sciences common stock on November 7, 2019. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.87 · Expires 2023-06-07 | Direct | 0 |
Reported balance
After 2019-11-08 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-11-08 · Disposition to issuer · Disposed 8,250 · Balance 0 F4: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $105,114 and 1,721 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $36.04 · Expires 2023-06-07 | Direct | 0 |
Reported balance
After 2019-11-08 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-11-08 · Disposition to issuer · Disposed 1,515 · Balance 0 F5: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $19,197 and 314 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.18 · Expires 2026-06-10 | Direct | 0 |
Reported balance
After 2019-11-08 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2019-11-08 · Disposition to issuer · Disposed 10,000 · Balance 0 F6: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $167,281 and 2,739 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.53 · Expires 2027-06-16 | Direct | 0 |
Reported balance
After 2019-11-08 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2019-11-08 · Disposition to issuer · Disposed 10,000 · Balance 0 F7: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $145,268 and 2,379 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $51.72 · Expires 2028-06-07 | Direct | 0 |
Reported balance
After 2019-11-08 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2019-11-08 · Disposition to issuer · Disposed 10,000 · Balance 0 F8: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $62,196 and 1,018 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $52.41 · Expires 2029-06-14 | Direct | 0 |
Reported balance
After 2019-11-08 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2019-11-08 · Disposition to issuer · Disposed 6,583 · Balance 0 F9: Disposed of in connection with the Merger, whereby such Issuer restricted stock unit award, whether or not vested, was cancelled in exchange for a cash payment of $39,074 and 640 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019. Pursuant to the applicable option award agreement, 100% of the unvested options held by the Reporting Person became fully vested following the change in control of the Issuer effected by the Merger. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of in connection with the acquisition of Issuer (the "Merger") by Exact Sciences Corporation ("Exact Sciences") pursuant to the Agreement and Plan of Merger, dated July 28, 2019 (the "Merger Agreement"), among Exact Sciences, Spring Acquisition Corp., and Issuer, whereby such shares of Issuer common stock were cancelled and converted into the right to receive a cash payment of $1,874,586 and 30,703 shares of Exact Sciences common stock, having a market value of $79.95 per share, based on the closing price of Exact Sciences common stock on November 7, 2019.
F2: Disposed of in connection with the Merger, whereby such Issuer restricted stock unit award, whether or not vested, was cancelled in exchange for a cash payment of $26,277 and 430 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019.
F3: Disposed of in connection with the Merger pursuant to the Merger Agreement, whereby such shares of Issuer common stock were cancelled and converted into the right to receive a cash payment of $166,888 and 2,733 shares of Exact Sciences common stock, having a market value of $79.95 per share, based on the closing price of Exact Sciences common stock on November 7, 2019.
F4: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $105,114 and 1,721 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019.
F5: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $19,197 and 314 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019.
F6: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $167,281 and 2,739 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019.
F7: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $145,268 and 2,379 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019.
F8: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $62,196 and 1,018 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019.
F9: Disposed of in connection with the Merger, whereby such Issuer restricted stock unit award, whether or not vested, was cancelled in exchange for a cash payment of $39,074 and 640 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019. Pursuant to the applicable option award agreement, 100% of the unvested options held by the Reporting Person became fully vested following the change in control of the Issuer effected by the Merger.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 12, 2026 Filed Jun 16, 2026 21:49 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantCommon Stock | 9,795 | $0.00 | $0.00 |
DisclosureSEC source: 0001339358-26-000002 · form4-06162026_090644.xml · nonDerivative · entry 1 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 165,060 F1 · shares: The reported securities are represented by restricted stock units ("RSUs"), of which the RSUs vests 100% on the earlier of the one year anniversary of grant or the day immediately before the first Annual Meeting that occurs after the grant date., subject to the Reporting Person's continuous service on each applicable vesting date. Read SEC document |
| June 09, 2026 Filed Jun 10, 2026 23:01 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantStock Option (right to buy) · Derivative | 13,300 | $0.00 Strike: $12.89 | $0.00 |
DisclosureSEC source: 0001193125-26-266233 · ownership.xml · derivative · entry 2 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,300 Underlying: Common Stock · 13,300 shares Expires 2036-06-08 F2 · derivative.exercise_date: This option was granted on June 9, 2026 with respect to 13,300 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant. Read SEC document |
| June 09, 2026 Filed Jun 10, 2026 23:01 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantCommon Stock | 9,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-266233 · ownership.xml · nonDerivative · entry 1 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 216,653 F1 · security: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit. Read SEC document |
| May 27, 2026 Filed May 29, 2026 20:30 UTC | Kyverna Therapeutics, Inc. KYTX · Entity 5452 | GrantStock Option (right to buy) · Derivative | 20,582 | $0.00 Strike: $8.59 | $0.00 |
DisclosureSEC source: 0001193125-26-248434 · ownership.xml · derivative · entry 3 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,582 Underlying: Common Stock · 20,582 shares Expires 2036-05-27 F2 · derivative.exercise_date: All of the shares subject to the option shall be fully vested and exercisable on the earlier of (i) May 27, 2027, and (ii) immediately prior to the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive. Read SEC document |
| May 27, 2026 Filed May 29, 2026 20:30 UTC | Kyverna Therapeutics, Inc. KYTX · Entity 5452 | GrantCommon Stock | 5,093 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-248434 · ownership.xml · nonDerivative · entry 1 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,727 F1 · shares: Represents a restricted stock unit award of common stock, which will vest in full on the earlier of (i) May 27, 2027, and (ii) immediately prior to the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive. Read SEC document |
| January 05, 2026 Filed Jan 7, 2026 21:05 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | PurchaseCommon Stock | 150,000 | $9.35 | $1,402,500.00 |
DisclosureSEC source: 0001193125-26-006288 · ownership.xml · nonDerivative · entry 1 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 207,453 F1 · kind: Reflects an open market purchase of shares of the Issuer's common stock by the Reporting Person in accordance with the Issuer's trading policies. F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.13 to $9.68, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares purchased by the reporting person on January 5, 2026 at each separate price. Read SEC document |
| June 13, 2025 Filed Jun 17, 2025 20:35 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantCommon Stock | 12,103 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-087424 · ownership.xml · nonDerivative · entry 1 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 155,265 F1 · shares: The reported securities are represented by restricted stock units which shall vest in one installment on the earlier of (i) June 13, 2026 or (ii) the day immediately prior to the first annual meeting of stockholders held by CareDx, Inc. after June 13, 2025. Read SEC document |
| June 11, 2025 Filed Jun 13, 2025 20:23 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantStock Option (right to buy) · Derivative | 11,450 | $0.00 Strike: $8.37 | $0.00 |
DisclosureSEC source: 0000950170-25-086223 · ownership.xml · derivative · entry 2 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,450 Underlying: Common Stock · 11,450 shares Expires 2035-06-10 F2 · derivative.exercise_date: This option was granted on June 11, 2025 with respect to 11,450 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant. Read SEC document |
| June 11, 2025 Filed Jun 13, 2025 20:23 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantCommon Stock | 8,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-086223 · ownership.xml · nonDerivative · entry 1 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,453 F1 · security: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit. Read SEC document |
| May 29, 2025 Filed Jun 2, 2025 22:30 UTC | Kyverna Therapeutics, Inc. KYTX · Entity 5452 | GrantStock Option (right to buy) · Derivative | 65,351 | $0.00 Strike: $2.63 | $0.00 |
DisclosureSEC source: 0000950170-25-080447 · ownership.xml · derivative · entry 3 Cohen Fred E · CIK 0001339358 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,351 Underlying: Common Stock · 65,351 shares Expires 2035-05-29 F2 · derivative.exercise_date: All of the shares subject to the option shall be fully vested and exercisable on the earlier of (i) May 29, 2026, and (ii) immediately prior to the date of the Issuer's 2026 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive. Read SEC document |
| May 29, 2025 Filed Jun 2, 2025 22:30 UTC | Kyverna Therapeutics, Inc. KYTX · Entity 5452 | GrantCommon Stock | 16,634 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-080447 · ownership.xml · nonDerivative · entry 1 Cohen Fred E · CIK 0001339358 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,634 F1 · shares: Represents a restricted stock unit award of common stock, which will vest in full on the earlier of (i) May 29, 2026, and (ii) immediately prior to the date of the Issuer's 2026 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive. Read SEC document |
| August 06, 2024 Filed Aug 8, 2024 13:11 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | GrantStock Option (right ot buy) · Derivative | 10,000 | $0.00 Strike: $15.16 | $0.00 |
DisclosureSEC source: 0001437749-24-025298 · rdgdoc.xml · derivative · entry 1 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Ordinary Shares · 10,000 shares Expires 2034-08-06 F1 · derivative.exercise_date: The shares underlying the stock option will vest in equal quarterly installments over a period of one year, subject to the director's Continuous Service (as defined in the 2017 Equity Incentive Plan) through such vesting dates. Read SEC document |
| June 14, 2024 Filed Jun 18, 2024 20:42 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantStock Option (right to buy) · Derivative | 16,048 | $0.00 Strike: $9.35 | $0.00 |
DisclosureSEC source: 0000950170-24-074946 · ownership.xml · derivative · entry 2 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,048 Underlying: Common Stock · 16,048 shares Expires 2034-06-14 F2 · derivative.exercise_date: 1/12th of the shares subject to this option shall vest on July 14, 2024, and 1/12th of the shares subject to the option shall vest monthly thereafter through June 14, 2025. Read SEC document |
| June 14, 2024 Filed Jun 18, 2024 20:42 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantCommon Stock | 10,570 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-074946 · ownership.xml · nonDerivative · entry 1 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 143,162 F1 · shares: The reported securities are represented by restricted stock units which shall vest in one installment on June 14, 2025. Read SEC document |
| June 14, 2024 Filed Jun 20, 2024 20:43 UTC Amendment | CareDx, Inc. CDNA · Entity 4344 | GrantStock Option (right to buy) · Derivative | 16,048 | $0.00 Strike: $14.19 | $0.00 |
DisclosureSEC source: 0000950170-24-075655 · ownership.xml · derivative · entry 1 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,048 Underlying: Common Stock · 16,048 shares Expires 2034-06-14 F1 · derivative.exercise_price: This amendment is being filed to correct the exercise price of the derivative security of the Stock Option (right to buy) reported on the original Form 4. F2 · derivative.exercise_date: 1/12th of the shares subject to this option shall vest on July 14, 2024, and 1/12th of the shares subject to the option shall vest monthly thereafter through June 14, 2025. Read SEC document |
| June 12, 2024 Filed Jun 14, 2024 20:19 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantStock Option (right to buy) · Derivative | 11,515 | $0.00 Strike: $25.85 | $0.00 |
DisclosureSEC source: 0000950170-24-073689 · ownership.xml · derivative · entry 2 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,515 Underlying: Common Stock · 11,515 shares Expires 2034-06-11 F2 · derivative.exercise_date: This option was granted on June 12, 2024 with respect to 11,515 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant. Read SEC document |
| June 12, 2024 Filed Jun 14, 2024 20:19 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantCommon Stock | 7,737 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-073689 · ownership.xml · nonDerivative · entry 1 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,453 F1 · security: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit. Read SEC document |
| May 23, 2024 Filed May 29, 2024 01:31 UTC | Progyny, Inc. PGNY · Entity 4521 | GrantStock Option (Right to Buy) · Derivative | 25,070 | $0.00 Strike: $27.15 | $0.00 |
DisclosureSEC source: 0001551306-24-000109 · wk-form4_1716946293.xml · derivative · entry 2 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,070 Underlying: Common Stock · 25,070 shares Expires 2034-05-22 F2 · derivative.exercise_date: The shares subject to the option will vest on May 23, 2025, subject to the Reporting Person's continued service on such date. Read SEC document |
| May 23, 2024 Filed May 29, 2024 01:31 UTC | Progyny, Inc. PGNY · Entity 4521 | GrantCommon Stock | 6,176 | $0.00 | $0.00 |
DisclosureSEC source: 0001551306-24-000109 · wk-form4_1716946293.xml · nonDerivative · entry 1 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,693 F1 · shares: Represents the number of shares of Issuer common stock underlying restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs will vest on May 23, 2025, subject to the Reporting Person's continued service on such date. Read SEC document |
| February 12, 2024 Filed Feb 15, 2024 00:03 UTC | Kyverna Therapeutics, Inc. KYTX · Entity 5452 | ConversionSeries B Redeemable Convertible Preferred Stock · Derivative | 7,356,162 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-015473 · ownership.xml · derivative · entry 4 Cohen Fred E · CIK 0001339358 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 1,616,348 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering. F3 · derivative.exercise_date: The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering. F3 · derivative.expiration_date: The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering. F2 · ownership.nature: Shares held directly by Vida Ventures, LLC ("Vida"). Vida Ventures Advisors, LLC is the investment advisor to Vida. Dr. Arie Belldegrun, Leonard Potter and the Reporting Person are the managing members of Vida Ventures Advisors, LLC, and may be deemed to share voting and dispositive power over the shares held by Vida, but each disclaims beneficial ownership of the shares held by Vida except to the extent of such person's pecuniary interest therein, if any. Read SEC document |
| February 12, 2024 Filed Feb 15, 2024 00:03 UTC | Kyverna Therapeutics, Inc. KYTX · Entity 5452 | ConversionSeries A-2 Redeemable Convertible Preferred Stock · Derivative | 8,830,901 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-015473 · ownership.xml · derivative · entry 3 Cohen Fred E · CIK 0001339358 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 1,940,388 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering. F3 · derivative.exercise_date: The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering. F3 · derivative.expiration_date: The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering. F2 · ownership.nature: Shares held directly by Vida Ventures, LLC ("Vida"). Vida Ventures Advisors, LLC is the investment advisor to Vida. Dr. Arie Belldegrun, Leonard Potter and the Reporting Person are the managing members of Vida Ventures Advisors, LLC, and may be deemed to share voting and dispositive power over the shares held by Vida, but each disclaims beneficial ownership of the shares held by Vida except to the extent of such person's pecuniary interest therein, if any. Read SEC document |
| February 12, 2024 Filed Feb 15, 2024 00:03 UTC | Kyverna Therapeutics, Inc. KYTX · Entity 5452 | ConversionSeries A-1 Redeemable Convertible Preferred Stock · Derivative | 4,401,771 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-015473 · ownership.xml · derivative · entry 2 Cohen Fred E · CIK 0001339358 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 967,188 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering. F3 · derivative.exercise_date: The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering. F3 · derivative.expiration_date: The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering. F2 · ownership.nature: Shares held directly by Vida Ventures, LLC ("Vida"). Vida Ventures Advisors, LLC is the investment advisor to Vida. Dr. Arie Belldegrun, Leonard Potter and the Reporting Person are the managing members of Vida Ventures Advisors, LLC, and may be deemed to share voting and dispositive power over the shares held by Vida, but each disclaims beneficial ownership of the shares held by Vida except to the extent of such person's pecuniary interest therein, if any. Read SEC document |
| February 12, 2024 Filed Feb 15, 2024 00:03 UTC | Kyverna Therapeutics, Inc. KYTX · Entity 5452 | ConversionCommon Stock | 4,523,924 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-015473 · ownership.xml · nonDerivative · entry 1 Cohen Fred E · CIK 0001339358 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 4,523,924 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents shares of the Issuer's Common Stock received upon conversion of shares of the reported series of preferred stock on a 1-for-4.5511 basis without payment of further consideration. F1 · price: Represents shares of the Issuer's Common Stock received upon conversion of shares of the reported series of preferred stock on a 1-for-4.5511 basis without payment of further consideration. F2 · ownership.nature: Shares held directly by Vida Ventures, LLC ("Vida"). Vida Ventures Advisors, LLC is the investment advisor to Vida. Dr. Arie Belldegrun, Leonard Potter and the Reporting Person are the managing members of Vida Ventures Advisors, LLC, and may be deemed to share voting and dispositive power over the shares held by Vida, but each disclaims beneficial ownership of the shares held by Vida except to the extent of such person's pecuniary interest therein, if any. Read SEC document |
| September 07, 2023 Filed Sep 8, 2023 19:42 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | GrantStock Option (right ot buy) · Derivative | 10,000 | $0.00 Strike: $16.85 | $0.00 |
DisclosureSEC source: 0001437749-23-025484 · rdgdoc.xml · derivative · entry 1 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Ordinary Shares · 10,000 shares Expires 2033-09-07 F1 · derivative.exercise_date: The shares underlying the stock option will vest in equal quarterly installments over a period of one year. Read SEC document |
| July 26, 2023 Filed Jul 28, 2023 22:06 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | GrantOrdinary Shares | 69,339 | $9.54 | $661,494.06 |
DisclosureSEC source: 0001437749-23-021073 · rdgdoc.xml · nonDerivative · entry 1 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · by Monograph Capital Partners, for which the reporting person is Chair and Chief Investment Officer Disclosed balance after: 69,339 F1 · shares: Represents the reporting person's proportionate interest in shares acquired by entities affiliated with Monograph Capital Partners, for which the reporting person is Chair and Chief Investment Officer Read SEC document |
| June 16, 2023 Filed Jun 21, 2023 22:50 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantCommon Stock · Derivative | 29,136 | $0.00 Strike: $7.96 | $0.00 |
DisclosureSEC source: 0001217234-23-000123 · wf-form4_168738779929036.xml · derivative · entry 2 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,136 Underlying: Common Stock · 29,136 shares Expires 2033-06-16 F2 · derivative.exercise_date: 1/12th of the shares subject to the option shall vest on July 16, 2023 and the shares subject to the option shall vest monthly thereafter through June 16, 2024. Read SEC document |
| June 16, 2023 Filed Jun 21, 2023 22:50 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantCommon Stock | 18,844 | $0.00 | $0.00 |
DisclosureSEC source: 0001217234-23-000123 · wf-form4_168738779929036.xml · nonDerivative · entry 1 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 132,592 F1 · shares: The reported securities are represented by restricted stock units which shall vest on June 16, 2024. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 20:26 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantStock Option (right to buy) · Derivative | 6,473 | $0.00 Strike: $45.20 | $0.00 |
DisclosureSEC source: 0001209191-23-037873 · doc4.xml · derivative · entry 2 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,473 Underlying: Common Stock · 6,473 shares Expires 2033-06-13 F2 · derivative.exercise_date: This option was granted on June 14, 2023 with respect to 6,473 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 20:26 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantCommon Stock | 4,425 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-037873 · doc4.xml · nonDerivative · entry 1 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,716 F1 · security: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit. Read SEC document |
| May 24, 2023 Filed May 26, 2023 21:01 UTC | Progyny, Inc. PGNY · Entity 4521 | GrantStock Option (Right to Buy) · Derivative | 18,350 | $0.00 Strike: $38.24 | $0.00 |
DisclosureSEC source: 0001628280-23-019974 · wf-form4_168513485961695.xml · derivative · entry 2 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,350 Underlying: Common Stock · 18,350 shares Expires 2033-05-23 F2 · derivative.exercise_date: The shares subject to the Option shall vest on May 24, 2024, subject to the Reporting Person continuing to provide service through such date. Read SEC document |
| May 24, 2023 Filed May 26, 2023 21:01 UTC | Progyny, Inc. PGNY · Entity 4521 | GrantCommon Stock | 4,385 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-019974 · wf-form4_168513485961695.xml · nonDerivative · entry 1 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,517 F1 · shares: Represents the number of shares of Issuer common stock underlying restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs shall vest on May 24, 2024, subject to the Reporting Person continuing to provide service through such date. Read SEC document |
| January 06, 2023 Filed Jan 9, 2023 22:27 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantCommon Stock | 1,062 | $0.00 | $0.00 |
DisclosureSEC source: 0001217234-23-000011 · wf-form4_167330324497335.xml · nonDerivative · entry 1 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,748 F1 · shares: Represents an automatic quarterly grant of common stock to the reporting person in lieu of cash for non-employee director compensation pursuant to the issuer's Outside Director Compensation Policy. Read SEC document |
| October 24, 2022 Filed Oct 26, 2022 21:36 UTC | Progyny, Inc. PGNY · Entity 4521 | GrantStock Option (Right to Buy) · Derivative | 1,460 | $0.00 Strike: $38.22 | $0.00 |
DisclosureSEC source: 0001628280-22-027102 · wf-form4_166682016685550.xml · derivative · entry 3 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,460 Underlying: Common Stock · 1,460 shares Expires 2032-10-23 F3 · price: This option was issued to the Reporting Person in lieu of annual retainers for board and committee service. The shares underlying the option reflect the payment in full of the Reporting Person's annual retainers of $29,038.20. F2 · derivative.exercise_date: The shares subject to the Option shall vest on May 23, 2023, subject to the Reporting Person continuing to provide service through such date. Read SEC document |
| October 24, 2022 Filed Oct 26, 2022 21:36 UTC | Progyny, Inc. PGNY · Entity 4521 | GrantStock Option (Right to Buy) · Derivative | 15,660 | $0.00 Strike: $38.22 | $0.00 |
DisclosureSEC source: 0001628280-22-027102 · wf-form4_166682016685550.xml · derivative · entry 2 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,660 Underlying: Common Stock · 15,660 shares Expires 2032-10-23 F2 · derivative.exercise_date: The shares subject to the Option shall vest on May 23, 2023, subject to the Reporting Person continuing to provide service through such date. Read SEC document |
| October 24, 2022 Filed Oct 26, 2022 21:36 UTC | Progyny, Inc. PGNY · Entity 4521 | GrantCommon Stock | 3,480 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-027102 · wf-form4_166682016685550.xml · nonDerivative · entry 1 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,132 F1 · shares: Represents the number of shares of Issuer common stock underlying restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs shall vest on May 23, 2023, subject to the Reporting Person continuing to provide service through such date. Read SEC document |
| October 04, 2022 Filed Oct 4, 2022 21:40 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantCommon Stock | 803 | $0.00 | $0.00 |
DisclosureSEC source: 0001217234-22-000173 · wf-form4_166491958892636.xml · nonDerivative · entry 1 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,686 F1 · shares: Represents an automatic quarterly grant of common stock to the reporting person in lieu of cash for non-employee director compensation pursuant to the issuer's Outside Director Compensation Policy. Read SEC document |
| June 16, 2022 Filed Jun 21, 2022 21:10 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantCommon Stock · Derivative | 7,606 | $0.00 Strike: $20.56 | $0.00 |
DisclosureSEC source: 0001217234-22-000125 · wf-form4_165584581900882.xml · derivative · entry 2 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,606 Underlying: Common Stock · 7,606 shares Expires 2032-06-16 F2 · derivative.exercise_date: 1/12th of the shares subject to the option shall vest on July 16, 2022 and the shares subject to the option shall vest monthly thereafter through June 16, 2023. Read SEC document |
| June 16, 2022 Filed Jun 21, 2022 21:10 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantCommon Stock | 4,863 | $0.00 | $0.00 |
DisclosureSEC source: 0001217234-22-000125 · wf-form4_165584581900882.xml · nonDerivative · entry 1 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,883 F1 · shares: The reported securities are represented by restricted stock units which shall vest on June 16, 2023. Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 22:22 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantStock Option (right to buy) · Derivative | 7,688 | $0.00 Strike: $38.49 | $0.00 |
DisclosureSEC source: 0001209191-22-037590 · doc4.xml · derivative · entry 2 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,688 Underlying: Common Stock · 7,688 shares Expires 2032-06-13 F2 · derivative.exercise_date: This option was granted on June 14, 2022 with respect to 7,688 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant. Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 22:22 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantCommon Stock | 5,197 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-037590 · doc4.xml · nonDerivative · entry 1 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,291 F1 · security: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit. Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 19:37 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $7.06 | $0.00 |
DisclosureSEC source: 0001437749-22-014772 · rdgdoc.xml · derivative · entry 1 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Ordinary Shares · 10,000 shares Expires 2032-06-08 F1 · derivative.exercise_date: The shares underlying the stock option will vest in equal quarterly installments over a period of one year. Read SEC document |
| October 24, 2021 Filed Oct 26, 2021 21:40 UTC | Progyny, Inc. PGNY · Entity 4521 | GrantStock Option (right to buy) · Derivative | 15,831 | $0.00 Strike: $63.21 | $0.00 |
DisclosureSEC source: 0001179110-21-009630 · edgar.xml · derivative · entry 2 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,831 Underlying: Common Stock · 15,831 shares Expires 2026-10-23 F2 · derivative.exercise_date: The shares subject to the Option shall vest on October 24, 2022, subject to the Reporting Person continuing to provide service through such date. Read SEC document |
| October 24, 2021 Filed Oct 26, 2021 21:40 UTC | Progyny, Inc. PGNY · Entity 4521 | GrantCommon Stock | 2,652 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-009630 · edgar.xml · nonDerivative · entry 1 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,652 F1 · shares: Represents the number of shares of Issuer common stock underlying restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs shall vest on October 24, 2022, subject to the Reporting Person continuing to provide service through such date. Read SEC document |
| June 23, 2021 Filed Jun 25, 2021 21:56 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantStock Option (right to buy) · Derivative | 3,382 | $0.00 Strike: $83.59 | $0.00 |
DisclosureSEC source: 0001209191-21-043362 · doc4.xml · derivative · entry 2 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,382 Underlying: Common Stock · 3,382 shares Expires 2031-06-22 F2 · derivative.exercise_date: This option was granted on June 23, 2021 with respect to 3,382 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant. Read SEC document |
| June 23, 2021 Filed Jun 25, 2021 21:56 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantCommon Stock | 2,094 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-043362 · doc4.xml · nonDerivative · entry 1 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,094 F1 · security: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit. Read SEC document |
| June 16, 2021 Filed Jun 21, 2021 23:56 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantStock Option (right to buy) · Derivative | 1,812 | $0.00 Strike: $88.70 | $0.00 |
DisclosureSEC source: 0001217234-21-000140 · wf-form4_162431978106643.xml · derivative · entry 2 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,812 Underlying: Common Stock · 1,812 shares Expires 2031-06-16 F2 · derivative.exercise_date: 1/12th of the shares subject to the option shall vest on July 16, 2021 and the shares subject to the option shall vest monthly thereafter through June 16, 2022. Read SEC document |
| June 16, 2021 Filed Jun 21, 2021 23:56 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantCommon Stock | 1,127 | $0.00 | $0.00 |
DisclosureSEC source: 0001217234-21-000140 · wf-form4_162431978106643.xml · nonDerivative · entry 1 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,020 F1 · shares: The reported securities are represented by restricted stock units which shall vest on June 16, 2022. Read SEC document |
| June 07, 2021 Filed Jun 9, 2021 17:45 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $17.98 | $0.00 |
DisclosureSEC source: 0001209191-21-039136 · doc4.xml · derivative · entry 1 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-06-07 F1 · derivative.exercise_date: The shares underlying the stock option will vest in equal quarterly installments over a period of one year. Read SEC document |
| January 20, 2021 Filed Jan 22, 2021 21:22 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $13.78 | $0.00 |
DisclosureSEC source: 0001209191-21-004866 · doc4.xml · derivative · entry 2 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 20,000 shares Expires 2029-01-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 22,166 shares as of January 20, 2021. Read SEC document |
| January 20, 2021 Filed Jan 22, 2021 21:22 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionCommon Stock | 20,000 | $13.78 | $275,600.00 |
DisclosureSEC source: 0001209191-21-004866 · doc4.xml · nonDerivative · entry 1 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.